573 related articles for article (PubMed ID: 25707733)
1. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.
Vital EM; Wittmann M; Edward S; Md Yusof MY; MacIver H; Pease CT; Goodfield M; Emery P
Arthritis Rheumatol; 2015 Jun; 67(6):1586-91. PubMed ID: 25707733
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.
Quelhas da Costa R; Aguirre-Alastuey ME; Isenberg DA; Saracino AM
JAMA Dermatol; 2018 Dec; 154(12):1432-1440. PubMed ID: 30383114
[TBL] [Abstract][Full Text] [Related]
3. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.
Hofmann SC; Leandro MJ; Morris SD; Isenberg DA
Lupus; 2013 Aug; 22(9):932-9. PubMed ID: 23894047
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus.
Li Q; Wu H; Liao W; Zhao M; Chan V; Li L; Zheng M; Chen G; Zhang J; Lau CS; Lu Q
J Autoimmun; 2018 Sep; 93():1-15. PubMed ID: 30017673
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous lupus erythematosus: issues in diagnosis and treatment.
Walling HW; Sontheimer RD
Am J Clin Dermatol; 2009; 10(6):365-81. PubMed ID: 19824738
[TBL] [Abstract][Full Text] [Related]
6. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications.
Chlebus E; Wolska H; Blaszczyk M; Jablonska S
J Am Acad Dermatol; 1998 Mar; 38(3):405-12. PubMed ID: 9520021
[TBL] [Abstract][Full Text] [Related]
7. B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus.
Jenks SA; Wei C; Bugrovsky R; Hill A; Wang X; Rossi FM; Cashman K; Woodruff MC; Aspey LD; Lim SS; Bao G; Drenkard C; Sanz I
Ann Rheum Dis; 2021 Sep; 80(9):1190-1200. PubMed ID: 34083207
[TBL] [Abstract][Full Text] [Related]
8. Skin CD4
Zhao Z; Zhu H; Li Q; Liao W; Chen K; Yang M; Long D; He Z; Zhao M; Wu H; Lu Q
J Autoimmun; 2022 Apr; 128():102811. PubMed ID: 35278775
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients.
Chanprapaph K; Tubtieng I; Pratumchat N; Thadanipon K; Rattanakaemakorn P; Suchonwanit P
Lupus; 2021 Apr; 30(5):785-794. PubMed ID: 33554715
[TBL] [Abstract][Full Text] [Related]
10. B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity.
Abernathy-Close L; Lazar S; Stannard J; Tsoi LC; Eddy S; Rizvi SM; Yee CM; Myers EM; Namas R; Lowe L; Reed TJ; Wen F; Gudjonsson JE; Kahlenberg JM; Berthier CC
Front Immunol; 2021; 12():775353. PubMed ID: 34868043
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced lupus erythematosus.
Marzano AV; Tavecchio S; Menicanti C; Crosti C
G Ital Dermatol Venereol; 2014 Jun; 149(3):301-9. PubMed ID: 24819757
[TBL] [Abstract][Full Text] [Related]
12. B cell biomarkers of rituximab responses in systemic lupus erythematosus.
Vital EM; Dass S; Buch MH; Henshaw K; Pease CT; Martin MF; Ponchel F; Rawstron AC; Emery P
Arthritis Rheum; 2011 Oct; 63(10):3038-47. PubMed ID: 21618204
[TBL] [Abstract][Full Text] [Related]
13. Selective expansions of T cells expressing V beta 8 and V beta 13 in skin lesions of patients with chronic cutaneous lupus erythematosus.
Furukawa F; Tokura Y; Matsushita K; Iwasaki-Inuzuka K; Onagi-Suzuki K; Yagi H; Wakita H; Takigawa M
J Dermatol; 1996 Oct; 23(10):670-6. PubMed ID: 8973031
[TBL] [Abstract][Full Text] [Related]
14. Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus.
Hofmann SC; Bosma A; Bruckner-Tuderman L; Vukmanovic-Stejic M; Jury EC; Isenberg DA; Mauri C
J Dermatol Sci; 2013 Jul; 71(1):22-8. PubMed ID: 23664188
[TBL] [Abstract][Full Text] [Related]
15. Biological therapies in the treatment of cutaneous lupus erythematosus.
Presto JK; Hejazi EZ; Werth VP
Lupus; 2017 Feb; 26(2):115-118. PubMed ID: 27687023
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients.
Vera-Recabarren MA; García-Carrasco M; Ramos-Casals M; Herrero C
Br J Dermatol; 2010 Jan; 162(1):91-101. PubMed ID: 19785596
[TBL] [Abstract][Full Text] [Related]
17. Panoramic view of clinical features of lupus erythematosus: a cross-sectional multicentre study from China.
Jin H; Zhou S; Yu Y; Zhao M; Wu H; Long H; Fu S; Wu R; Yin H; Liao J; Luo S; Liu Y; Zhang Q; Zhang P; Tan Y; Luo S; Huang X; Li F; Ling G; Lu Q
Lupus Sci Med; 2023 Mar; 10(1):. PubMed ID: 36941021
[TBL] [Abstract][Full Text] [Related]
18. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.
Md Yusof MY; Shaw D; El-Sherbiny YM; Dunn E; Rawstron AC; Emery P; Vital EM
Ann Rheum Dis; 2017 Nov; 76(11):1829-1836. PubMed ID: 28684557
[TBL] [Abstract][Full Text] [Related]
19. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
[TBL] [Abstract][Full Text] [Related]
20. Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea.
Oh EH; Kim EJ; Ro YS; Ko JY
J Dermatol; 2018 Apr; 45(4):436-443. PubMed ID: 29423919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
